Recombinant tissue plasminogen activator (rtPA) is licensedfor thrombolytic therapy in ischemic stroke if administered within 3 hours of stroke onset in selected patients (to be extended to 4.5 hours in some countries). However, many patients who could benefit from rtPA are not offered it and there is evidence that rtPA could benefit many patients who do not meet current license criteria. Furthermore, the patient characteristics that might assist in stratifying risk and benefit and the latest time at which thrombolysis may be effective remain unknown. Objectives The objectives of this study were to assess the safety and efficacy of thrombolytic agents used in acute treatment of ischemic stroke, factors that might influence risk or benefit, and estimate if current data can identify the latest time window for treatment
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.